Erlotinib Completed Phase 1 Trials for Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01515137Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma